Literature DB >> 9564475

Influenza vaccine efficacy in young, healthy adults.

I Grotto1, Y Mandel, M S Green, N Varsano, M Gdalevich, I Ashkenazi, J Shemer.   

Abstract

Findings concerning influenza vaccine efficacy in young, healthy adults are inconsistent. A high incidence of influenza in the winter of 1995 provided an opportunity to study the efficacy of influenza vaccine among young, healthy military personnel. Influenza activity was confirmed by isolation of influenza A and B viruses from nasopharyngeal swab specimens from hospitalized soldiers. Self-administered questionnaires concerning vaccination status and disease symptoms were used in two study groups: recruits and veteran soldiers serving in different camps. Six hundred eighty-four individuals had received influenza vaccine and 652 had not. Vaccine efficacy was found to be 38.1% (P = .002) for preventing febrile illness with or without symptoms and slightly higher (41.6%; P < .001) for preventing fever together with upper respiratory tract symptoms. The current influenza vaccine significantly reduced febrile illness among healthy military personnel.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564475     DOI: 10.1086/513934

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Quantifying influenza vaccine efficacy and antigenic distance.

Authors:  Vishal Gupta; David J Earl; Michael W Deem
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

2.  Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification.

Authors:  A E Krafft; K L Russell; A W Hawksworth; S McCall; M Irvine; L T Daum; J L Connoly; A H Reid; J C Gaydos; J K Taubenberger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses.

Authors:  Dennis J Faix; Anthony W Hawksworth; Christopher A Myers; Christian J Hansen; Ryan G Ortiguerra; Rebecca Halpin; David Wentworth; Laura A Pacha; Erica G Schwartz; Shawn M S Garcia; Angelia A Eick-Cost; Christopher D Clagett; Surender Khurana; Hana Golding; Patrick J Blair
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

4.  A novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains.

Authors:  Keyao Pan; Krystina C Subieta; Michael W Deem
Journal:  Protein Eng Des Sel       Date:  2010-11-30       Impact factor: 1.650

5.  Influenza outbreak control in confined settings.

Authors:  Ran D Balicer; Michael Huerta; Yuval Levy; Nadav Davidovitch; Itamar Grotto
Journal:  Emerg Infect Dis       Date:  2005-04       Impact factor: 6.883

Review 6.  Prevention and control of influenza in persons with chronic obstructive pulmonary disease.

Authors:  Pedro Plans-Rubió
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

7.  Why Does Israel Lead the World in COVID-19 Vaccinations? Applying Mass Casualty Event Principles to COVID-19 Vaccination Programs.

Authors:  Carmit Rapaport; Isaac Ashkenazi
Journal:  Int J Environ Res Public Health       Date:  2021-05-18       Impact factor: 3.390

8.  The Clinical Effect of Seasonal Flu Vaccination on Health-Related Quality of Life.

Authors:  Yusuke Yoshino; Yoshitaka Wakabayashi; Takatoshi Kitazawa
Journal:  Int J Gen Med       Date:  2021-05-27

Review 9.  Vaccines for preventing influenza in healthy adults.

Authors:  Vittorio Demicheli; Tom Jefferson; Eliana Ferroni; Alessandro Rivetti; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

10.  Respiratory syncytial virus: an important cause of acute respiratory illness among young adults undergoing military training.

Authors:  Matthew K O'Shea; Christopher Pipkin; Patricia A Cane; Gregory C Gray
Journal:  Influenza Other Respir Viruses       Date:  2007 Sep-Nov       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.